email:
password:

Register for Free! RSS Feed
Random Faqqing
Why Should I Register For Idiotechnica.com?
The question is, why shouldn't you register. Click Here To Find Out.
firefox_logo
idiotechnica.com uses CSS3 and is optimized for viewing in Firefox versions 3+
U.S. District Court Judge Invalidates Human Gene Patent

http://csem.flinders.edu.au/research/laboratories/CG/dna.jpg In what could be a landmark decision, a U.S. district court judge has struck down patents on two genes; BRCA1 & BRCA2 which are linked to cancer in humans.

The decision could have an impact on the approximately 20% of human genes already patented, and could have a major effect on future genetic research. It could also fundamentally change the ways in which biotech companies do business.
Leave Comment:
Comment
Submit Post

Posts: Science and Nature / U.S. District Court Judge Invalidates Human Gene Patent

share this thread on facebook

Posted By: Virginia
03/30/10 11:02 PM

really interesting, I had never even thought about that this before. it's really horrible that some companies actually own genes.
Posted By: Dylan
03/30/10 11:06 PM

I'm not really familiar with U.S. patent laws, but I wouldn't be opposed to granted patents on genes if the patents themselves were extremely short (e.g. ~5 years). Just long enough for the original company to reap the initial profits before the information is made public.
Posted By: Virginia
03/30/10 11:09 PM

agreed
Posted By: Virginia
03/30/10 11:15 PM

on second thought, however, think of how much more progress and technology could be achieved if they used an open source system instead. this way i would imagine the costs of research and design would be reduced. everyone's working for the same goal right, saving lives? it should be more focused on that but perhaps the competition between companies, such as capitalism, facilitates the availability of treatments rather then hinders them and therefore is a better move.


Posted By: Dylan
03/30/10 11:31 PM

Sure, individuals might be working towards a common selfless goal, but investors are generally working towards profits. An open source system might expedite some research while leaving more major research projects (eg. the human genome project) much more risky for biotech firms to fund.